130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

E.Cohen; R.Govindan; M.Kozloff; A.Mauer; P.Hoffman; T.Karrison; J.Stein; L.Szeto; R.Salgia; E.Vokes

首页> 外文期刊>European Journal of Cancer Supplements >130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

【24h】

130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

机译：序贯贝伐单抗和厄洛替尼联合贝伐单抗和化疗治疗一线IIIB或IV期非小细胞肺癌（NSCLC）的130 POSTER II期临床试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共2页
作者
E.Cohen; R.Govindan; M.Kozloff; A.Mauer; P.Hoffman; T.Karrison; J.Stein; L.Szeto; R.Salgia; E.Vokes;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) [J] . Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第3期

机译：贝伐单抗和厄洛替尼（BE）一线治疗晚期非鳞状非小细胞肺癌（NSCLC）（IIIB / IV期），然后在疾病进展时进行铂类化疗（CT）：一项多中心II期试验（ SAKK 19/05）
2. 9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression - a multicenter phase II trial of SAKK [J] . F.Zappa, C.Droege, D.Betticher, European Journal of Cancer Supplements . 2009,第2期

机译：9147贝伐单抗和厄洛替尼作为晚期（IIIB / IV期）非鳞状非小细胞肺癌（NSCLC）的一线治疗，然后在疾病进展时进行铂类化疗（CT）-SAKK的多中心II期临床试验
3. 6513 ORAL A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) [J] . A.Dingemans, H.J.M.Groen, E.F.Smit European Journal of Cancer Supplements . 2007,第4期

机译：6513口服厄洛替尼（E）和贝伐单抗（B）在先前未经治疗的IIIB / IV期非小细胞肺癌（NSCLC）患者中的II期临床研究
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer [O] . Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, -1

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐珠单抗继之贝伐单抗维持治疗
7. P3-087: Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV Non-small cell lung cancer (NSCLC) [O] . Govindan Ramaswamy, Cohen Ezra E., Kozloff Mark F., 2007

机译：P3-087：测序贝伐单抗和厄洛替尼与贝伐单抗联合化疗用于一线IIIB或IV期非小细胞肺癌（NSCLC）的II期试验

130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅